Boston Scientific accounts are for healthcare professionals only.
Boston Scientific is advancing heart failure innovations backed by strong clinical evidence to enable earlier detection, continuous monitoring, and more precise treatment—while empowering clinicians to manage important heart failure risk factors more effectively to help patients live longer, healthier lives.
Heart Failure Solutions
Care Continuum Diagnostics & Monitoring
Arrhythmia Detection5
Heart Failure Therapy
Heart Failure Risk Factor & Comorbidity Management
Atrial Fibrillation Management & Stroke Prevention
Hypertension
Stay informed
Sign up for our mailing list to stay up to date on the latest in our Heart Failure solutions.
Customer Service
Find contact information, technical support, ordering information and other resources for heart failure clinicians.
1. HeartLogic™ is a heart failure diagnostic tool that uses multiple sensors to proactively alert clinicians via the LATITUDE™ NXT Remote Patient Management System.
2. LATITUDE™ Remote Patient Management System is used to monitor your patients’ device data between scheduled appointments.
3. BodyGuardian™ 360 is a Remote Patient Monitoring Platform used to manage chronic conditions like heart failure, using connected devices to track vitals and enable early intervention.
4. The BodyGuardian™ products and affiliated services are associated with Boston Scientific Cardiac Diagnostics, Inc., a wholly owned subsidiary of Boston Scientific.
5. Device detected arrhythmia information in a symptomatic patient is a known risk factor of Heart Failure decompensation.
6. The LUX-Dx II+™ ICM System is not indicated for the monitoring or diagnosis of heart failure but rather is designed to monitor and record cardiac arrhythmias.
7. The FARAPULSE™ PFA Platform is indicated for the isolation of pulmonary veins for patients with drug-refractory, symptomatic persistent and paroxysmal atrial fibrillation and for posterior wall ablation for patients with drug-refractory, symptomatic paroxsymal atrial fibrillation.
8. The WATCHMAN FLX™ Pro Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation.
9. The SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, ST-elevation MI (STEMI), non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries ≥2.25 mm to ≤5.00 mm in diameter in lesions ≤44 mm in length and for high bleeding risk patients with coronary arteries ≥2.25 mm to ≤5.00 mm in diameter in lesions ≤34 mm in length.
10. The AGENT™ Paclitaxel-Coated Balloon Catheter is intended to be used after appropriate vessel preparation in adult patients undergoing PCI in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).
11. Caution: The TIVUS™ Intravascular Ultrasound System is an Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale.